Neon Therapeutics is developing novel neoantigen-targeted T cell therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both personal and precision neoantigen-targeted T cell therapy candidates. Neon’s most advanced program is NEO-PTC-01, its personal neoantigen-targeted T cell therapy candidate consisting of multiple T cell populations targeting the most therapeutically relevant neoantigens from each patient’s tumor.

PRECLINICAL DEVELOPMENT
PHASE 1
LATER STAGE

NEO-PTC-01

Personal neoantigen T cell therapy
2nd line metastatic melanoma
2nd line metastatic ovarian cancer
TARGET
DISCOVERY
TARGET
VALIDATION
PRECLINICAL
DEVELOPMENT
PHASE 1
LATER STAGE

NEO-STC-01

Shared neoantigens T cell therapy
RAS pancreatic cancer
Undisclosed solid tumors